| Nasdaq: VICL
Vical, Inc. researches and develops biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company's core technology involves the insertion of DNA into plasmids designed to deliver the desired genes into cells in the body. Its development programs include Infectious disease vaccines for use in high-risk populations; Infectious disease vaccines for general pediatric, adolescent and adult populations; cancer vaccines or immunotherapies; and gene-based delivery of angiogenic growth factors for treatment of cardiovascular diseases. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.